Navigation Links
Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
Date:4/22/2011

TOKYO, April 22, 2011 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that the company has received its first marketing approval for LIXIANA® (JAN: Edoxaban Tosilate Hydrate, INN:edoxaban) 15 mg and 30 mg tablets, by the Ministry of Health, Labor and Welfare in Japan.

Edoxaban, which is being developed solely by Daiichi Sankyo, is a once-daily, oral anticoagulant that specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Results from clinical studies supported the approval of edoxaban for the prevention of venous thromboembolism (VTE) in patients with total knee arthroplasty, total hip arthroplasty and hip fracture surgery.

Commenting on receiving the first national marketing authorization for edoxaban, Joji Nakayama, president and CEO of Daiichi Sankyo, said, "We are pleased to confirm that an exciting milestone has been reached, and we are confident that edoxaban will make a great contribution to VTE prevention after major orthopedic surgery. Daiichi Sankyo also remains committed to exploring the potential for edoxaban in several other indications, and has a robust global clinical trial program."

The global clinical development program for edoxaban is focused on several indications, including stroke prevention in atrial fibrillation (AF) patients, and treatment and prevention of recurrent venous thromboembolism. In the ENGAGE AF-TIMI 48 study, an ongoing, multinational, randomized, double-blind, Phase III study, the efficacy and safety of edoxaban in preventing stroke and systemic embolic events in patients with AF are being examined in more than 21,000 patients with AF in 46 countries.(1)  

The ENGAGE AF-TIMI 48 study is the largest trial in this indication to date. Also currently ongoing, the HOKUSAI VTE study is the largest single, double-blind, randomized, multinational Phase III study in the treatment and prevention of recurre
'/>"/>

SOURCE Daiichi Sankyo Company, Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
3. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
6. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
7. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
8. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
9. Daiichi Sankyo Co, Ltd. Joins the National Cherry Blossom Festival in Washington D.C. as Centennial Celebration Committee Co-Chair
10. Daiichi Sankyo/Lilly Respond to ACCF/AHA Clinical Alert on Antiplatelet Therapy
11. Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... and ,S-HERTOGENBOSCH, The Netherlands ... its subsidiary, HealthLink International received its ISO 13485 certificate ... fulfillment and administrative services for medical device manufacturers throughout ... Explains Rick Hughes , President of HealthLink Europe ... ISO 13485 certified facilities, two in Europe ...
(Date:4/1/2015)...  New York College of Health Professions announces a ... with U.S. Patent #8,996,098 donated by its Chairman under ... surgical instrument that allows surgeons to view and compare ... the traditional format of a slide that is used ... surgery, thus providing the surgeon real time analysis and ...
(Date:4/1/2015)... , April 1, 2015 Morgan & ... against the board of directors of Auspex Pharmaceuticals, Inc. ... possible breaches of fiduciary duty and other violations of ... to Teva Pharmaceuticals Industries Ltd.  The transaction is valued ... shares of Auspex and would like to learn more ...
Breaking Medicine Technology:Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 2Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 3
... (Amex: NEP ), a,medical device company, announced today ... its OLpur(TM) H2H module and OLpur(TM) MD220 filter,for End ... pleased to have reached this important milestone.,There is a ... over dialysis for the ESRD patient, including,studies supporting a ...
... Expansion Plans for SB-509-701 Phase 2 Clinical Trial for Treatment of ... ... SAN FRANCISCO, June 6 Sangamo BioSciences,Inc. (Nasdaq: SGMO ) announced ... in subjects with moderate to,severe diabetic neuropathy. Additionally, based upon positive initial ...
Cached Medicine Technology:Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products 2Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products 3Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 2Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 3Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 4Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs 5
(Date:4/1/2015)... New Jersey Governor First Spouse ... Spouses from across the country in sponsoring the ... World Down Syndrome Day(WDSD), to increase awareness of, ... of Down syndrome cognition research. , In addition ... American Samoa, Arizona, California, Colorado, Delaware, Florida, Guam, ...
(Date:4/1/2015)... 2015 BioPlus Specialty Pharmacy ... has released a new app to keep health care ... chronic hepatitis C virus (HCV) infection. This ‘HCV Treatment ... from the American Association for the Study of Liver ... new direct-acting oral medications to treat HCV have been ...
(Date:4/1/2015)... BC (PRWEB) April 01, 2015 Dr ... announced that she is now offering her patients an ... services. Patients can participate in “Beauty Days”, which is ... by Dr Roz Kamani’s Kitsilano Skin Care Clinic. It ... directly tell patients about the latest products and services ...
(Date:4/1/2015)... 01, 2015 South Florida’s newest concept ... of Authority (PCOA) approval from the State of Florida. ... ongoing development of a retirement community that will offer ... and spiritual development. , America’s aging population is experiencing ... housing needs of seniors, according to a recent report ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 Health Advocate™, ... and a subsidiary of West Corporation, today launched its ... http://blog.healthadvocate.com and through the Health Advocate member ... consumers get, and stay, healthy. , “We’re pleased to ... to the public,” said Martin Rosen, Executive Vice President, ...
Breaking Medicine News(10 mins):Health News:Governor First Spouses Join with New Jersey First Lady Mary Pat Christie to Support Advances in Biomedical Research to Treat Down Syndrome Cognitive Impairment 2Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:Dr Roz Kamani Now Offers Patients The Opportunity to Learn About Latest Products and Services 2Health News:Casa Sant’Angelo Receives Approval for New Retirement Living 2Health News:Health Advocate Launches New Health and Wellness Blog 2
... outlined a new path for potential therapies to combat ... new understanding of the bodys earliest immune response in ... their findings, to be published in the May edition ... the first evidence describing how viral agents, such as ...
... web-based solution will improve care and enhance ... efficiencies and revenue at 10 Florida locations, TAMPA, ... seamless integration to enhance patient care delivery and,business office ... has selected Sage Software,s Intergy EHR by,Sage Electronic Health ...
... /PRNewswire-FirstCall/ - Traxxec,Ltd, the UK subsidiary of Columbia ... announces that, in line with the licence agreement ... the Interpack conference,and trade show in Dusseldorf, 24-30 ... be present at this,meeting giving the Traxxec RFID ...
... Innovative Thinking, Powerful Creative Drive Success, NEW ... and brand-development firm and member of the Omnicom ... the Year, Category III by Medical,Advertising News at ... in New York., Distinguished by innovative thinking, ...
... PITTSBURGH, April 29 One of the most ... of workers,compensation insurance driven by claims made against ... contain their workers, compensation,exposure and control costs, the ... and Grochmal has published The 2008 Employers, Guide ...
... are expected to participate in the sixth annual ... Massachusetts and,finishing in White Plains, New York, this ... and awareness for the fatal neuromuscular disorder,amyotrophic lateral ... strong this summer, the Trek is distributing cowbells ...
Cached Medicine News:Health News:Immune system kick-started in moist nasal lining in sinusitis, asthma and colds 2Health News:Immune system kick-started in moist nasal lining in sinusitis, asthma and colds 3Health News:Florida Cardiology Chooses Intergy by Sage to Integrate Practice Management and Electronic Health Records 2Health News:Florida Cardiology Chooses Intergy by Sage to Integrate Practice Management and Electronic Health Records 3Health News:Columbia River Resources Inc subsidiary, Traxxec Ltd, reports coverage of its technology at Interpack 2008 (Pink Sheets OTC - CRVR.pk) 2Health News:Columbia River Resources Inc subsidiary, Traxxec Ltd, reports coverage of its technology at Interpack 2008 (Pink Sheets OTC - CRVR.pk) 3Health News:Flashpoint Medica Named Agency of Year by Medical Advertising News 2Health News:New Workers' Compensation Resource Guide Available For Pennsylvania Employers 2Health News:More Cowbell! To end ALS, Riders of the Tri-State Trek Cycle 270 Miles - Making Noise and Raising Money! 2Health News:More Cowbell! To end ALS, Riders of the Tri-State Trek Cycle 270 Miles - Making Noise and Raising Money! 3
Hardy Micro Dissector, bayonet. Working distance 4 1/4" (120 mm). Angled up, tip width: 2 mm....
Cushing-landolt bi-valve speculum for trans-sphenoidal hypophysectomie....
Cushing pituitary scoop, malleable, silver-plated....
... Implant system. Material that has a modulus ... The result is an implant that meets ... while optimizing the fusion environment through an ... design with 5 and 10 degrees of ...
Medicine Products: